Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease.

Singh UP, Singh NP, Guan H, Busbee B, Price RL, Taub DD, Mishra MK, Fayad R, Nagarkatti M, Nagarkatti PS.

Int Rev Immunol. 2014 Jan;33(1):23-33. doi: 10.3109/08830185.2013.809071. Epub 2013 Jul 10. Review.

2.

Leptin antagonist ameliorates chronic colitis in IL-10⁻/⁻ mice.

Singh UP, Singh NP, Guan H, Busbee B, Price RL, Taub DD, Mishra MK, Fayad R, Nagarkatti M, Nagarkatti PS.

Immunobiology. 2013 Dec;218(12):1439-51. doi: 10.1016/j.imbio.2013.04.020. Epub 2013 May 13.

3.

Development and characterization of high affinity leptins and leptin antagonists.

Shpilman M, Niv-Spector L, Katz M, Varol C, Solomon G, Ayalon-Soffer M, Boder E, Halpern Z, Elinav E, Gertler A.

J Biol Chem. 2011 Feb 11;286(6):4429-42. doi: 10.1074/jbc.M110.196402. Epub 2010 Nov 30.

5.

Restricted leptin antagonism as a therapeutic approach to treatment of autoimmune diseases.

Babaei A, Zarkesh-Esfahani SH, Bahrami E, Ross RJ.

Hormones (Athens). 2011 Jan-Mar;10(1):16-26. Review.

6.

Regulatory T cells, leptin and angiogenesis.

Pucino V, De Rosa V, Procaccini C, Matarese G.

Chem Immunol Allergy. 2014;99:155-69. doi: 10.1159/000353557. Epub 2013 Oct 17. Review.

PMID:
24217608
7.

Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities.

Motilva V, Talero E, Calvo JR, Villegas I, Alarcón-de-la-Lastra C, Sánchez-Fidalgo S.

Curr Pharm Des. 2008;14(1):71-95. Review.

PMID:
18220820
8.

Altered immunoregulatory profile during anti-tumour necrosis factor treatment of patients with inflammatory bowel disease.

Grundström J, Linton L, Thunberg S, Forsslund H, Janczewska I, Befrits R, van Hage M, Gafvelin G, Eberhardson M.

Clin Exp Immunol. 2012 Aug;169(2):137-47. doi: 10.1111/j.1365-2249.2012.04600.x.

9.

Leptin, immune responses and autoimmune disease. Perspectives on the use of leptin antagonists.

Peelman F, Iserentant H, Eyckerman S, Zabeau L, Tavernier J.

Curr Pharm Des. 2005;11(4):539-48. Review.

PMID:
15725070
10.

Emerging immunological targets in inflammatory bowel disease.

Monteleone G, Pallone F, MacDonald TT.

Curr Opin Pharmacol. 2011 Dec;11(6):640-5. doi: 10.1016/j.coph.2011.09.013. Epub 2011 Oct 12. Review.

PMID:
22000933
11.

Leptin: linking adipocyte metabolism with cardiovascular and autoimmune diseases.

Peelman F, Waelput W, Iserentant H, Lavens D, Eyckerman S, Zabeau L, Tavernier J.

Prog Lipid Res. 2004 Jul;43(4):283-301. Review.

PMID:
15234549
12.

Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment.

Veltkamp C, Anstaett M, Wahl K, Möller S, Gangl S, Bachmann O, Hardtke-Wolenski M, Länger F, Stremmel W, Manns MP, Schulze-Osthoff K, Bantel H.

Gut. 2011 Oct;60(10):1345-53. doi: 10.1136/gut.2010.217117. Epub 2011 Apr 1.

PMID:
21459928
13.

The therapeutic potential of carbon monoxide for inflammatory bowel disease.

Takagi T, Uchiyama K, Naito Y.

Digestion. 2015;91(1):13-8. doi: 10.1159/000368765. Epub 2015 Jan 20. Review.

14.

Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.

Nakase H, Okazaki K, Tabata Y, Chiba T.

J Gastroenterol. 2003 Mar;38 Suppl 15:59-62. Review.

PMID:
12698874
15.

From airway inflammation to inflammatory bowel disease: eotaxin-1, a key regulator of intestinal inflammation.

Adar T, Shteingart S, Ben Ya'acov A, Bar-Gil Shitrit A, Goldin E.

Clin Immunol. 2014 Jul;153(1):199-208. doi: 10.1016/j.clim.2014.04.012. Epub 2014 Apr 29. Review.

PMID:
24786916
16.

Development of leptin antagonists and their potential use in experimental biology and medicine.

Gertler A.

Trends Endocrinol Metab. 2006 Nov;17(9):372-8. Epub 2006 Sep 28. Review.

PMID:
17010639
17.

Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.

Yousef M, Pichyangkura R, Soodvilai S, Chatsudthipong V, Muanprasat C.

Pharmacol Res. 2012 Jul;66(1):66-79. doi: 10.1016/j.phrs.2012.03.013. Epub 2012 Mar 28.

PMID:
22475725
18.

Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?

O'Sullivan M.

Proc Nutr Soc. 2015 Feb;74(1):5-12. doi: 10.1017/S0029665114001621. Epub 2014 Dec 10. Review.

PMID:
25490986
19.
20.

Leptin-activity blockers: development and potential use in experimental biology and medicine.

Gertler A, Solomon G.

Can J Physiol Pharmacol. 2013 Nov;91(11):873-82. doi: 10.1139/cjpp-2013-0012. Epub 2013 Apr 22. Review.

PMID:
24117254

Supplemental Content

Support Center